Table 1

PICOS design for identification of relevant studies for the scoping review

PopulationInclusion: Human cancer patients aged 18+, any sex and stage of cancer. Cancer diagnosis confirmed according to diagnostic criteria relevant to the cancer group, which can combine histology, biochemistry and imaging.
Exclusion: Inclusion of non-cancer patients.
InterventionInclusion: Any sarcopenia assessment on cross-sectional MRI or CT. Although MRI and CT can cover any anatomical landmark, the review will prioritise measures from imaging done during routine cancer imaging.
Exclusion: Routine cancer staging includes cranium, chest, abdomen and pelvis, meaning that limb-based imaging will not be included.
ComparisonInclusion: Non-sarcopenia cohort per the study’s definition.
Exclusion: Studies without non-sarcopenia cohort (feasibility studies).
OutcomeSurvival, disease-free survival, treatment-related toxicity or complications, postoperative stays.
Study DesignInclusion: Clinical trials or observational studies will be included
Exclusion: Case reports, abstracts, conference presentations, expert opinions, reviews and meta-analyses. Where multiple studies share populations only the largest study will be included.